UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000024143
Receipt number R000027801
Scientific Title efficacy of aterosclerosis of tofacitinib in rheumatoid arthritis
Date of disclosure of the study information 2016/09/23
Last modified on 2017/05/27 09:28:32

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

efficacy of aterosclerosis of tofacitinib in rheumatoid arthritis

Acronym

efficacy of aterosclerosis of tofacitinib in rheumatoid arthritis

Scientific Title

efficacy of aterosclerosis of tofacitinib in rheumatoid arthritis

Scientific Title:Acronym

efficacy of aterosclerosis of tofacitinib in rheumatoid arthritis

Region

Japan


Condition

Condition

atherosclerosis efficacy of tofacitinib in RA

Classification by specialty

Clinical immunology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

safety and efficacy of tofacitinib in RA

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2


Developmental phase

Phase IV


Assessment

Primary outcomes

AS values in 54 weeks

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is considered as a block.

Blocking

YES

Concealment

No need to know


Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Other

Interventions/Control_1

RA patients with moderate to severe active disease despite MTX treatment (disease activity score: DAS28>3.2)

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

75 years-old >=

Gender

Male and Female

Key inclusion criteria

RA patients with moderate to severe active disease despite MTX treatment (disease activity score: DAS28>3.2)

Key exclusion criteria

NP

Target sample size

50


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name kensuke kume

Organization

hiroshima clinic

Division name

rheumatology

Zip code


Address

Higashi kannon 20-16, Hiroshima, Japan

TEL

082-232-0707

Email

kumekensuke@live.jp


Public contact

Name of contact person

1st name
Middle name
Last name kensuke kume

Organization

hiroshima clinic

Division name

rheumatology

Zip code


Address

Higashi kannon 20-16, Hiroshima, Japan

TEL

082-232-0707

Homepage URL


Email

kumekensuke@live.jp


Sponsor or person

Institute

hiroshima clinic

Institute

Department

Personal name



Funding Source

Organization

hiroshima clinic

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2016 Year 09 Month 23 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results

under submitting to journal

Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2015 Year 04 Month 01 Day

Date of IRB


Anticipated trial start date

2015 Year 05 Month 01 Day

Last follow-up date

2016 Year 08 Month 31 Day

Date of closure to data entry


Date trial data considered complete

2016 Year 09 Month 23 Day

Date analysis concluded



Other

Other related information



Management information

Registered date

2016 Year 09 Month 23 Day

Last modified on

2017 Year 05 Month 27 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000027801


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name